Human anti-rabies IgG therapy regulatory update

Kamada submitted a BLA to FDA for its human anti-rabies IgG therapy as post-exposure treatment of rabies infection. The company expects an FDA response in mid-2017. Kedrion Group (Lucca, Italy) has ex...